Insights into the implementation of Fibronectin 1 in the cartilage tissue engineering

Aladal，Murad1,2; You，Wei1; Huang，Rongxiang1; Huang，Jianghong1; Deng，Zhiqin1; Duan，Li1; Wang，Daping2,3; Li，Wencui1; Sun，Wei1

2022-04-01

10.1016/j.biopha.2022.112782

BIOMEDICINE & PHARMACOTHERAPY   影响因子和分区

0753-3322

1950-6007

Recently, cartilage tissue engineering has become a cornerstone to treat cartilage degeneration and osteoarthritis (OA). Fibronectin1 (FN1) is described as multiple functional glycoproteins that play an essential role in chondrogenic and osteogenic differentiation. Few studies reported the potential of FN1 to enhance tissue engineering and reduce the death of chondrocytes in OA. Further, FN1 possesses multiple binding domains including collagen, integrin, and heparin that can interact with heparan sulfate proteoglycans at the surface of chondrocyte leading to promote cell signaling and differentiation. Recent studies suggested that FN1 can promote chondrocyte differentiation by upregulating TGF-β/PI3K/Akt pathways. Further, FN1 can inhibit the apoptosis of chondrocytes by preventing the release of metalloproteinases through lowering the expression of p-PI3K/PI3K and p-AKT/AKT pathways. However, the use of FN1 in cartilage repair studies using animal models or clinical trials was rarely reported. Therefore, this article provides new insights into the importance of FN1 in cartilage tissue engineering to encourage more studies concerning FN1 in cartilage repair studies. Further, we provided new suggestions for advanced applications of FN1 to treat OA and cartilage degeneration.

Cartilage regeneration Chondrocyte Fibronectin 1 Osteoarthritis

SCI

英语

通讯

International Science and Technology Cooperation Project of Guangdong Province 2019, China[1035043] ; Sanming Project of Shenzhen Health and Family Planning Commission[SZSM201612086] ; Shenzhen Key Medical Discipline Construction Fund[SZXK025] ; key clinical discipline of Guangdong Province, Orthopedics[2000005] ; [1038051]

Research & Experimental Medicine ; Pharmacology & Pharmacy

Medicine, Research & Experimental ; Pharmacology & Pharmacy

WOS:000819836500005

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER

2-s2.0-85125547642

Scopus

1.Hand and Foot Surgery Department,Shenzhen Second People's Hospital (The First Hospital Affiliated to Shenzhen University),Shenzhen,518000,China
2.Shenzhen Key Laboratory of Tissue Engineering,Shenzhen Laboratory of Digital Orthopedic Engineering,Guangdong Provincial Research Center for Artificial Intelligence and Digital Orthopedic Technology,Shenzhen Second People's Hospital (The First Hospital Affiliated to Shenzhen University,Health Science Center),Shenzhen,518035,China
3.Department of Biomedical Engineering,Southern University of Science and Technology,Shenzhen,518055,China

Aladal，Murad,You，Wei,Huang，Rongxiang,et al. Insights into the implementation of Fibronectin 1 in the cartilage tissue engineering[J]. BIOMEDICINE & PHARMACOTHERAPY,2022,148.

Aladal，Murad.,You，Wei.,Huang，Rongxiang.,Huang，Jianghong.,Deng，Zhiqin.,...&Sun，Wei.(2022).Insights into the implementation of Fibronectin 1 in the cartilage tissue engineering.BIOMEDICINE & PHARMACOTHERAPY,148.

Aladal，Murad,et al."Insights into the implementation of Fibronectin 1 in the cartilage tissue engineering".BIOMEDICINE & PHARMACOTHERAPY 148(2022).